Medicare 2027 Part D Changes: What Federal Retirees With FEHB Need to Know
Medicare’s Part D prescription drug benefit looks very different in 2026 than it did three years ago, and CMS’s final 2027 Medicare Advantage and Part D rule — issued April 2, 2026 — locks in another round of changes. For federal retirees who pair Medicare with FEHB, the most consequential shifts are already in motion: a hard $2,100 annual out-of-pocket cap in 2026 (rising to $2,400 in 2027), the second wave of Medicare-negotiated drug prices, and a different set of marketing and Star Ratings rules than what was originally proposed. Each of these affects whether you should enroll in Part D, lean on FEHB’s prescription coverage, or rethink your overall coordination strategy.
This post breaks down what’s actually changing, how it interacts with your FEHB plan, and the decisions worth revisiting before next Open Season.
The Part D Out-of-Pocket Cap and Why It Matters for FEHB Retirees
Starting in 2025, the Inflation Reduction Act capped Medicare Part D beneficiaries’ annual out-of-pocket prescription drug costs at $2,000. CMS confirmed the cap rose to $2,100 in 2026 and announced it will rise to $2,400 in 2027 (per the CMS 2027 Announcement). Before 2025, the catastrophic coverage threshold could easily push high-utilizing beneficiaries past $7,000 in personal spending.
For federal retirees, the cap fundamentally changes the math on whether to enroll in a stand-alone Part D plan. In years past, many retirees with multiple maintenance medications stuck with FEHB’s prescription coverage because it had no annual catastrophic exposure cliff. Now Part D offers a known ceiling, and that ceiling is competitive with — or in some cases lower than — what FEHB pharmacy benefits will cost a heavy user over the course of the year.
The trade-off is no longer obvious. A retiree on three brand-name drugs might pay $4,000–$6,000 in coinsurance under a typical FEHB pharmacy tier, while a Part D plan with the same drug list would cap out at $2,100 in 2026 and $2,400 in 2027. That gap is real, but it has to be weighed against Part D premiums (CMS projects the average stand-alone Part D plan total premium will be roughly $34.50 per month in 2026, down from $38.31 in 2025), the loss of FEHB pharmacy integration, and whether your spouse or dependents also need pharmacy coverage under a single plan.
Medicare Negotiated Drug Prices: Round Two in 2027
The first ten Medicare-negotiated drugs took effect in January 2026 — covering medications like Eliquis, Jardiance, Januvia, and Xarelto — and produced negotiated prices ranging from 38% to 79% below pre-negotiation list prices, according to CMS. In 2027, the negotiation list expands to 15 additional drugs that CMS announced on January 17, 2025, including widely prescribed treatments for diabetes, autoimmune conditions, and cancer.
For federal retirees, the relevance is twofold:
- If you take any of the listed drugs, your Part D out-of-pocket costs may drop significantly, even before you hit the cap, because the negotiated price flows through cost-sharing.
- FEHB plans are not bound by Medicare-negotiated prices. Your FEHB pharmacy benefit pays the price the FEHB carrier has negotiated independently, which may or may not match. Some FEHB plans negotiate aggressively; others rely more heavily on rebates that benefit the plan, not the retiree at the counter.
If you’re on one of the negotiated drugs and currently using FEHB only, it’s worth pricing the same drug under a stand-alone Part D plan available in your ZIP code. The difference at the pharmacy counter can be $100–$400 per month for a single drug.
What the Final 2027 CMS Rule Actually Changes
CMS issued the proposed CY 2027 Medicare Advantage and Part D rule in November 2025 and finalized it on April 2, 2026. The final version is meaningfully different from the proposal in several places — particularly around marketing. Here are the changes federal retirees should know about:
Marketing and Agent/Broker Rules Were Loosened, Not Tightened
Despite earlier industry concerns, the final 2027 rule rolled back several restrictions that had been put in place in prior years. Specifically, CMS eliminated the 48-hour Scope of Appointment (SOA) waiting period, eliminated the 12-hour delay between contact and a marketing/sales event, and removed the 60-second timing requirement for Third-Party Marketing Organization (TPMO) disclosures. The practical effect is fewer delays between a federal retiree expressing interest in a Medicare Advantage plan and being able to enroll — but also fewer guardrails on aggressive marketing. Federal retirees should still slow down and compare plans carefully during Open Season; the regulatory friction that used to do some of that work has been reduced.
Star Ratings Adjustments
The final rule did not implement the Excellent Health Outcomes for All (Health Equity Index) reward for 2027 Star Ratings, removed 11 administrative/process measures, and added a Part C Depression Screening measure for the 2027 measurement year that will affect 2029 Star Ratings. Star Ratings still drive plan bonus payments and what plans are available in each market — read the underlying measures, not just the headline number, before enrolling.
FEHB Coordination: Should You Suspend, Drop, or Keep Both?
The most common federal retiree question is whether to keep paying FEHB premiums after enrolling in Medicare Part A and Part B. The 2026–2027 changes don’t alter the basic options, but they do shift the math on a few specific scenarios.
Keeping FEHB plus original Medicare (A and B): Still the dominant strategy. Most FEHB plans waive deductibles and copays once Medicare pays primary, and you keep FEHB’s catastrophic protection. A stand-alone Part D plan is generally not needed because FEHB’s prescription coverage qualifies as creditable.
Suspending FEHB to enroll in Medicare Advantage: Increasingly common. You preserve the right to re-enroll in FEHB later if the Medicare Advantage plan disappoints. The 2027 final rule’s looser marketing constraints make it easier to be courted by MA plans, but the decision still requires careful comparison of provider networks and prescription formularies. For an in-depth breakdown of how to keep both coverages working together, see our guide on Medicare and FEHB: How Federal Retirees Can Get the Best of Both.
Dropping FEHB entirely: Rarely the right move. Once you drop it, you generally cannot get it back. The premium savings rarely justify the risk of being shut out for life. If you’re tempted, read our piece on FEHB Premiums in Retirement before deciding.
The Part B IRMAA Question Most Federal Retirees Miss
The 2027 CMS rule does not change the Income-Related Monthly Adjustment Amount (IRMAA) brackets, but the underlying income thresholds adjust each year. In 2026, an individual filer with modified adjusted gross income at or below $109,000 (or $218,000 for joint filers) pays no IRMAA surcharge on top of the standard Part B premium, which is $202.90 per month in 2026 (up from $185.00 in 2025, per CMS).
For federal retirees, the IRMAA two-year lookback can be a stealth tax. A large TSP Roth conversion, a one-time TSP withdrawal to pay off a mortgage, or even the year you cash out unused annual leave can push your modified AGI into a higher bracket — and your Part B premium will reflect that two years later. This is exactly the kind of scenario covered in our post on Federal Retirement Tax Planning.
What Federal Employees Approaching Retirement Should Do Now
If you’re within five years of retirement, three concrete actions will pay off when the 2027 rules take effect:
- Get a list of every medication you (and your spouse) currently take, including dose and quantity. Without this list, you cannot compare FEHB pharmacy costs against Part D plans in a meaningful way. Print it; do not rely on memory.
- Check the 2027 negotiated drug list against your prescription list. CMS publishes the negotiated drugs by name and dosage on Medicare.gov. If you take any of them, the Part D math changes in your favor.
- Run two Medicare scenarios at age 65: FEHB + Medicare A only, and FEHB + Medicare A and B. The decision affects your premiums, your IRMAA exposure, and your out-of-pocket maximums for the rest of your life. Don’t decide on intuition.
The Bottom Line
The 2027 final CMS rule is not a single dramatic change. It is a continuation of the Inflation Reduction Act’s reshaping of Part D, combined with looser Medicare Advantage marketing rules and an evolving Star Ratings methodology. For federal retirees, the practical effect is that Part D is now a genuinely competitive option — not just for catastrophic protection but for routine maintenance medications. The right answer still depends on which drugs you take, what your FEHB plan covers, and how your income affects IRMAA. But the answer is no longer obviously “stick with FEHB and skip Part D.”
Open Season is months away, but the planning starts now. Fed Pilot’s free federal retirement workshops walk through Medicare coordination, FEHB plan selection, and the dollar-by-dollar math of getting your retirement health coverage right.
